{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T05:39:23Z","timestamp":1774935563044,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T00:00:00Z","timestamp":1698969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T00:00:00Z","timestamp":1698969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Host immunity involves various immune cells working in concert to achieve balanced immune response. Host immunity interacts with tumorigenic process impacting disease outcome. Clusters of different immune cells may reveal unique host immunity in relation to breast cancer progression. CIBERSORT algorithm was used to estimate relative abundances of 22 immune cell types in 3 datasets, METABRIC, TCGA, and our study. The cell type data in METABRIC were analyzed for cluster using unsupervised hierarchical clustering (UHC). The UHC results were employed to train machine learning models. Kaplan\u2013Meier and Cox regression survival analyses were performed to assess cell clusters in association with relapse-free and overall survival. Differentially expressed genes by clusters were interrogated with IPA for molecular signatures. UHC analysis identified two distinct immune cell clusters, clusters A (83.2%) and B (16.8%). Memory B cells, plasma cells, CD8 positive T cells, resting memory CD4 T cells, activated NK cells, monocytes, M1 macrophages, and resting mast cells were more abundant in clusters A than B, whereas regulatory T cells and M0 and M2 macrophages were more in clusters B than A. Patients in cluster A had favorable survival. Similar survival associations were also observed in other independent studies. IPA analysis showed that pathogen-induced cytokine storm signaling pathway, phagosome formation, and T cell receptor signaling were related to the cell type clusters. Our finding suggests that different immune cell clusters may indicate distinct immune responses to tumor growth, suggesting their potential for disease management.<\/jats:p>","DOI":"10.1038\/s41598-023-45932-4","type":"journal-article","created":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T11:01:46Z","timestamp":1699009306000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Machine learning-based cluster analysis of immune cell subtypes and breast cancer survival"],"prefix":"10.1038","volume":"13","author":[{"given":"Zhanwei","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dionyssios","family":"Katsaros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junlong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholetta","family":"Biglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenda Y.","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peiwen","family":"Fei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingeng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harvey","family":"Risch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herbert","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,3]]},"reference":[{"issue":"6","key":"45932_CR1","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41568-021-00347-z","volume":"21","author":"KJ Hiam-Galvez","year":"2021","unstructured":"Hiam-Galvez, K. J., Allen, B. M. & Spitzer, M. H. Systemic immunity in cancer. Nat. Rev. Cancer 21(6), 345\u2013359. https:\/\/doi.org\/10.1038\/s41568-021-00347-z (2021).","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"45932_CR2","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12(4), 252\u2013264. https:\/\/doi.org\/10.1038\/nrc3239 (2012).","journal-title":"Nat. Rev. Cancer"},{"issue":"6382","key":"45932_CR3","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359(6382), 1350\u20131355. https:\/\/doi.org\/10.1126\/science.aar4060 (2018).","journal-title":"Science"},{"key":"45932_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/nyas.12105","volume":"1284","author":"MD Vesely","year":"2013","unstructured":"Vesely, M. D. & Schreiber, R. D. Cancer immunoediting: Antigens, mechanisms, and implications to cancer immunotherapy. Ann. N. Y. Acad. Sci. 1284, 1\u20135. https:\/\/doi.org\/10.1111\/nyas.12105 (2013).","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"3","key":"45932_CR5","doi-asserted-by":"publisher","first-page":"738","DOI":"10.3390\/cancers12030738","volume":"12","author":"RK Vaddepally","year":"2020","unstructured":"Vaddepally, R. K., Kharel, P., Pandey, R., Garje, R. & Chandra, A. B. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers (Basel) 12(3), 738. https:\/\/doi.org\/10.3390\/cancers12030738 (2020).","journal-title":"Cancers (Basel)"},{"issue":"6","key":"45932_CR6","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.3390\/cancers13061388","volume":"13","author":"M Mencoboni","year":"2021","unstructured":"Mencoboni, M. et al. Effectiveness and safety of immune checkpoint inhibitors for patients with advanced non small-cell lung cancer in real-world: Review and meta-analysis. Cancers (Basel) 13(6), 1388. https:\/\/doi.org\/10.3390\/cancers13061388 (2021).","journal-title":"Cancers (Basel)"},{"issue":"33","key":"45932_CR7","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1200\/JCO.20.02110","volume":"38","author":"AMM Eggermont","year":"2020","unstructured":"Eggermont, A. M. M. et al. Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: Updated results from the EORTC 1325-MG\/KEYNOTE-054 trial. J. Clin. Oncol. 38(33), 3925\u20133936. https:\/\/doi.org\/10.1200\/JCO.20.02110 (2020).","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"45932_CR8","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber, J. et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N. Engl. J. Med. 377(19), 1824\u20131835. https:\/\/doi.org\/10.1056\/NEJMoa1709030 (2017).","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"45932_CR9","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer, R. J. et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 378(14), 1277\u20131290. https:\/\/doi.org\/10.1056\/NEJMoa1712126 (2018).","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"45932_CR10","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.jtho.2019.10.004","volume":"15","author":"NE Ready","year":"2020","unstructured":"Ready, N. E. et al. Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: Results from the CheckMate 032 randomized cohort. J. Thorac. Oncol. 15(3), 426\u2013435. https:\/\/doi.org\/10.1016\/j.jtho.2019.10.004 (2020).","journal-title":"J. Thorac. Oncol."},{"issue":"9","key":"45932_CR11","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMc1916859","volume":"382","author":"MD Hellmann","year":"2020","unstructured":"Hellmann, M. D. & Ramalingam, S. S. Nivolumab plus ipilimumab in non-small-cell lung cancer. N. Engl. J. Med. 382(9), 875. https:\/\/doi.org\/10.1056\/NEJMc1916859 (2020).","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"45932_CR12","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid, P. et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N. Engl. J. Med. 379(22), 2108\u20132121. https:\/\/doi.org\/10.1056\/NEJMoa1809615 (2018).","journal-title":"N. Engl. J. Med."},{"issue":"10265","key":"45932_CR13","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"Cortes, J. et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): A randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 396(10265), 1817\u20131828. https:\/\/doi.org\/10.1016\/S0140-6736(20)32531-9 (2020).","journal-title":"Lancet"},{"issue":"1","key":"45932_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-021-06291-8","volume":"189","author":"MR Kearney","year":"2021","unstructured":"Kearney, M. R., McGuinness, J. E. & Kalinsky, K. Clinical trial data and emerging immunotherapeutic strategies: Hormone receptor-positive, HER2- negative breast cancer. Breast Cancer Res. Treat. 189(1), 1\u201313. https:\/\/doi.org\/10.1007\/s10549-021-06291-8 (2021).","journal-title":"Breast Cancer Res. Treat."},{"issue":"11","key":"45932_CR15","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.3394","volume":"19","author":"DF Quail","year":"2013","unstructured":"Quail, D. F. & Joyce, J. A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19(11), 1423\u20131437. https:\/\/doi.org\/10.1038\/nm.3394 (2013).","journal-title":"Nat. Med."},{"issue":"2","key":"45932_CR16","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1002\/path.2803","volume":"223","author":"M Allen","year":"2011","unstructured":"Allen, M. & Louise, J. J. Jekyll and Hyde: The role of the microenvironment on the progression of cancer. J. Pathol. 223(2), 162\u2013176. https:\/\/doi.org\/10.1002\/path.2803 (2011).","journal-title":"J. Pathol."},{"issue":"4","key":"45932_CR17","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41568-019-0125-9","volume":"19","author":"H Salmon","year":"2019","unstructured":"Salmon, H., Remark, R., Gnjatic, S. & Merad, M. Host tissue determinants of tumour immunity. Nat. Rev. Cancer 19(4), 215\u2013227. https:\/\/doi.org\/10.1038\/s41568-019-0125-9 (2019).","journal-title":"Nat. Rev. Cancer"},{"issue":"23","key":"45932_CR18","doi-asserted-by":"publisher","first-page":"6132","DOI":"10.3390\/cancers13236132","volume":"13","author":"K Matsuo","year":"2021","unstructured":"Matsuo, K., Yoshie, O. & Nakayama, T. Multifaceted roles of chemokines and chemokine receptors in tumor immunity. Cancers (Basel) 13(23), 6132. https:\/\/doi.org\/10.3390\/cancers13236132 (2021).","journal-title":"Cancers (Basel)"},{"issue":"6","key":"45932_CR19","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1111\/his.13695","volume":"73","author":"M Althobiti","year":"2018","unstructured":"Althobiti, M. et al. Heterogeneity of tumour-infiltrating lymphocytes in breast cancer and its prognostic significance. Histopathology 73(6), 887\u2013896. https:\/\/doi.org\/10.1111\/his.13695 (2018).","journal-title":"Histopathology"},{"issue":"10","key":"45932_CR20","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/s41571-020-0387-x","volume":"17","author":"SP Haen","year":"2020","unstructured":"Haen, S. P., Loffler, M. W., Rammensee, H. G. & Brossart, P. Towards new horizons: Characterization, classification and implications of the tumour antigenic repertoire. Nat. Rev. Clin. Oncol. 17(10), 595\u2013610. https:\/\/doi.org\/10.1038\/s41571-020-0387-x (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"45932_CR21","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3389\/fimmu.2020.00276","volume":"11","author":"V Janelle","year":"2020","unstructured":"Janelle, V., Rulleau, C., Del Testa, S., Carli, C. & Delisle, J. S. T-cell immunotherapies targeting histocompatibility and tumor antigens in hematological malignancies. Front. Immunol. 11, 276. https:\/\/doi.org\/10.3389\/fimmu.2020.00276 (2020).","journal-title":"Front. Immunol."},{"issue":"11","key":"45932_CR22","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1360458","volume":"6","author":"S Safi","year":"2017","unstructured":"Safi, S. et al. Functional T cells targeting tumor-associated antigens are predictive for recurrence-free survival of patients with radically operated non-small cell lung cancer. Oncoimmunology 6(11), e1360458. https:\/\/doi.org\/10.1080\/2162402X.2017.1360458 (2017).","journal-title":"Oncoimmunology"},{"issue":"2","key":"45932_CR23","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.cllc.2018.09.008","volume":"20","author":"YK Chae","year":"2019","unstructured":"Chae, Y. K. et al. Association of tumor mutational burden with DNA repair mutations and response to anti-PD-1\/PD-L1 therapy in non-small-cell lung cancer. Clin. Lung Cancer 20(2), 88-96 e6. https:\/\/doi.org\/10.1016\/j.cllc.2018.09.008 (2019).","journal-title":"Clin. Lung Cancer"},{"issue":"2","key":"45932_CR24","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/imm.13101","volume":"158","author":"CC Liu","year":"2019","unstructured":"Liu, C. C., Steen, C. B. & Newman, A. M. Computational approaches for characterizing the tumor immune microenvironment. Immunology 158(2), 70\u201384. https:\/\/doi.org\/10.1111\/imm.13101 (2019).","journal-title":"Immunology"},{"issue":"5","key":"45932_CR25","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12(5), 453\u2013457. https:\/\/doi.org\/10.1038\/nmeth.3337 (2015).","journal-title":"Nat. Methods"},{"issue":"12","key":"45932_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002194","volume":"13","author":"HR Ali","year":"2016","unstructured":"Ali, H. R., Chlon, L., Pharoah, P. D., Markowetz, F. & Caldas, C. Patterns of immune infiltration in breast cancer and their clinical implications: A gene-expression-based retrospective study. PLoS Med. 13(12), e1002194. https:\/\/doi.org\/10.1371\/journal.pmed.1002194 (2016).","journal-title":"PLoS Med."},{"issue":"1","key":"45932_CR27","doi-asserted-by":"publisher","first-page":"5499","DOI":"10.1038\/s41467-019-13329-5","volume":"10","author":"X Tekpli","year":"2019","unstructured":"Tekpli, X. et al. An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment. Nat. Commun. 10(1), 5499. https:\/\/doi.org\/10.1038\/s41467-019-13329-5 (2019).","journal-title":"Nat. Commun."},{"issue":"5","key":"45932_CR28","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies, M. et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat. Med. 24(5), 541\u2013550. https:\/\/doi.org\/10.1038\/s41591-018-0014-x (2018).","journal-title":"Nat. Med."},{"issue":"2","key":"45932_CR29","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s10549-020-05954-2","volume":"185","author":"M Sadeghalvad","year":"2021","unstructured":"Sadeghalvad, M., Mohammadi-Motlagh, H. R. & Rezaei, N. Immune microenvironment in different molecular subtypes of ductal breast carcinoma. Breast Cancer Res. Treat. 185(2), 261\u2013279. https:\/\/doi.org\/10.1007\/s10549-020-05954-2 (2021).","journal-title":"Breast Cancer Res. Treat."},{"key":"45932_CR30","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3389\/fonc.2017.00156","volume":"7","author":"L Wein","year":"2017","unstructured":"Wein, L. et al. Clinical validity and utility of tumor-infiltrating lymphocytes in routine clinical practice for breast cancer patients: Current and future directions. Front. Oncol. 7, 156. https:\/\/doi.org\/10.3389\/fonc.2017.00156 (2017).","journal-title":"Front. Oncol."},{"issue":"7","key":"45932_CR31","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1093\/jnci\/djx268","volume":"110","author":"C Desmedt","year":"2018","unstructured":"Desmedt, C. et al. Immune infiltration in invasive lobular breast cancer. J. Natl. Cancer Inst. 110(7), 768\u2013776. https:\/\/doi.org\/10.1093\/jnci\/djx268 (2018).","journal-title":"J. Natl. Cancer Inst."},{"issue":"2 Suppl 2","key":"45932_CR32","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.jaci.2009.12.980","volume":"125","author":"DD Chaplin","year":"2010","unstructured":"Chaplin, D. D. Overview of the immune response. J. Allergy Clin. Immunol. 125(2 Suppl 2), S3-23. https:\/\/doi.org\/10.1016\/j.jaci.2009.12.980 (2010).","journal-title":"J. Allergy Clin. Immunol."},{"issue":"6","key":"45932_CR33","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","volume":"140","author":"SI Grivennikov","year":"2010","unstructured":"Grivennikov, S. I., Greten, F. R. & Karin, M. Immunity, inflammation, and cancer. Cell 140(6), 883\u2013899. https:\/\/doi.org\/10.1016\/j.cell.2010.01.025 (2010).","journal-title":"Cell"},{"issue":"5","key":"45932_CR34","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/s12276-020-0435-8","volume":"52","author":"JR Hwang","year":"2020","unstructured":"Hwang, J. R., Byeon, Y., Kim, D. & Park, S. G. Recent insights of T cell receptor-mediated signaling pathways for T cell activation and development. Exp. Mol. Med. 52(5), 750\u2013761. https:\/\/doi.org\/10.1038\/s12276-020-0435-8 (2020).","journal-title":"Exp. Mol. Med."},{"key":"45932_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-021-00973-w","author":"X Sun","year":"2021","unstructured":"Sun, X. et al. Effector memory cytotoxic CD3(+)\/CD8(+)\/CD45RO(+) T cells are predictive of good survival and a lower risk of recurrence in triple-negative breast cancer. Mod. Pathol. https:\/\/doi.org\/10.1038\/s41379-021-00973-w (2021).","journal-title":"Mod. Pathol."},{"issue":"1","key":"45932_CR36","doi-asserted-by":"publisher","first-page":"5668","DOI":"10.1038\/s41467-021-25962-0","volume":"12","author":"D Hammerl","year":"2021","unstructured":"Hammerl, D. et al. Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer. Nat. Commun. 12(1), 5668. https:\/\/doi.org\/10.1038\/s41467-021-25962-0 (2021).","journal-title":"Nat. Commun."},{"issue":"20","key":"45932_CR37","doi-asserted-by":"publisher","first-page":"5628","DOI":"10.1158\/1078-0432.CCR-21-0343","volume":"27","author":"JM Carter","year":"2021","unstructured":"Carter, J. M. et al. Characteristics and spatially defined immune (micro)landscapes of early-stage PD-L1-positive triple-negative breast cancer. Clin. Cancer Res. 27(20), 5628\u20135637. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0343 (2021).","journal-title":"Clin. Cancer Res."},{"key":"45932_CR38","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/978-1-4939-7493-1_12","volume":"1711","author":"B Chen","year":"2018","unstructured":"Chen, B., Khodadoust, M. S., Liu, C. L., Newman, A. M. & Alizadeh, A. A. Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol. Biol. 1711, 243\u2013259. https:\/\/doi.org\/10.1007\/978-1-4939-7493-1_12 (2018).","journal-title":"Methods Mol. Biol."},{"issue":"7403","key":"45932_CR39","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature10983","volume":"486","author":"C Curtis","year":"2012","unstructured":"Curtis, C. et al. The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups. Nature 486(7403), 346\u2013352. https:\/\/doi.org\/10.1038\/nature10983 (2012).","journal-title":"Nature"},{"key":"45932_CR40","doi-asserted-by":"publisher","first-page":"11479","DOI":"10.1038\/ncomms11479","volume":"7","author":"B Pereira","year":"2016","unstructured":"Pereira, B. et al. The somatic mutation profiles of 2433 breast cancers refines their genomic and transcriptomic landscapes. Nat. Commun. 7, 11479. https:\/\/doi.org\/10.1038\/ncomms11479 (2016).","journal-title":"Nat. Commun."},{"issue":"5","key":"45932_CR41","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2(5), 401\u2013404. https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0095 (2012).","journal-title":"Cancer Discov."},{"issue":"269","key":"45932_CR42","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6(269), pl1. https:\/\/doi.org\/10.1126\/scisignal.2004088 (2013).","journal-title":"Sci. Signal."},{"issue":"4","key":"45932_CR43","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/blood-2017-03-735654","volume":"130","author":"MA Jensen","year":"2017","unstructured":"Jensen, M. A., Ferretti, V., Grossman, R. L. & Staudt, L. M. The NCI genomic data commons as an engine for precision medicine. Blood 130(4), 453\u2013459. https:\/\/doi.org\/10.1182\/blood-2017-03-735654 (2017).","journal-title":"Blood"},{"issue":"1","key":"45932_CR44","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s10549-012-1952-5","volume":"133","author":"L Mu","year":"2012","unstructured":"Mu, L. et al. Favorable outcome associated with an IGF-1 ligand signature in breast cancer. Breast Cancer Res. Treat. 133(1), 321\u2013331. https:\/\/doi.org\/10.1007\/s10549-012-1952-5 (2012).","journal-title":"Breast Cancer Res. Treat."},{"issue":"8","key":"45932_CR45","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/sj.bjc.6604689","volume":"99","author":"L Mu","year":"2008","unstructured":"Mu, L. et al. TGF-beta1 genotype and phenotype in breast cancer and their associations with IGFs and patient survival. Br. J. Cancer 99(8), 1357\u20131363. https:\/\/doi.org\/10.1038\/sj.bjc.6604689 (2008).","journal-title":"Br. J. Cancer"},{"issue":"22","key":"45932_CR46","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkq871","volume":"38","author":"W Shi","year":"2010","unstructured":"Shi, W., Oshlack, A. & Smyth, G. K. Optimizing the noise versus bias trade-off for Illumina whole genome expression BeadChips. Nucleic Acids Res. 38(22), e204. https:\/\/doi.org\/10.1093\/nar\/gkq871 (2010).","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"45932_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v033.i01","volume":"33","author":"J Friedman","year":"2010","unstructured":"Friedman, J., Hastie, T. & Tibshirani, R. Regularization paths for generalized linear models via coordinate descent. J. Stat. Softw. 33(1), 1\u201322 (2010).","journal-title":"J. Stat. Softw."},{"issue":"20","key":"45932_CR48","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.1093\/bioinformatics\/bti623","volume":"21","author":"T Sing","year":"2005","unstructured":"Sing, T., Sander, O., Beerenwinkel, N. & Lengauer, T. ROCR: Visualizing classifier performance in R. Bioinformatics 21(20), 3940\u20133941. https:\/\/doi.org\/10.1093\/bioinformatics\/bti623 (2005).","journal-title":"Bioinformatics"},{"issue":"1\u20132","key":"45932_CR49","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","volume":"160","author":"MS Rooney","year":"2015","unstructured":"Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G. & Hacohen, N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160(1\u20132), 48\u201361. https:\/\/doi.org\/10.1016\/j.cell.2014.12.033 (2015).","journal-title":"Cell"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-45932-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-45932-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-45932-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T11:02:48Z","timestamp":1699009368000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-45932-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,3]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["45932"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-45932-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,3]]},"assertion":[{"value":"16 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18962"}}